Crucell « Terug naar discussie overzicht

Crucell kondigt licentieovk met ProFribix aan

33 Posts, Pagina: 1 2 » | Laatste

Omlaag ↓

[verwijderd] 17 december 2007 08:06

Crucell kondigt licentieovk met ProFribix aan
Crucell: ovk betreft Star technologie

(MORE TO FOLLOW) Dow Jones Newswires

Grand Cru 17 december 2007 08:08

Crucell Announces Research License Agreement with ProFibrix on STAR® Technology

Leiden, The Netherlands, 17 December 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with ProFibrix BV. The license with The Netherlands based ProFibrix covers the production of specific forms of human fibrinogen, a protein involved in haemostasis (blood clotting) and tissue repair. Financial details of the agreement were not disclosed.

About STAR® Technology
STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® technology and the widely used Chinese Hamster Ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements, that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs. STAR® technology was discovered by Dr. Arie Otte (Nature Biotechnology 2003 May 21, (5)) who founded Chromagenics B.V., a spin-off company of the University of Amsterdam, acquired by Crucell in March 2004.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com

[verwijderd] 17 december 2007 08:33

Crucell sluit STAR-licentieovereenkomst met ProFibrix
17 december 2007, 8:29 uur | FD.nl/Betten
AMSTERDAM (FD.nl/Betten) - Crucell heeft een niet-exclusieve STAR-licentieovereenkomst voor onderzoek gesloten met het in Nederland gevestigde ProFibrix. Dat heeft het biotechnologiebedrijf maandag bekendgemaakt.

Financiele details van de overeenkomst worden niet naar buiten gebracht. De overeenkomst is gebaseerd op de productie van specifieke vormen van menselijke fibrinogeen, een eiwit betrokken bij bloedstolling, en weefselherstel.

Martijn Mom
martijn@bfn.com

(c) Het Financieele Dagblad in samenwerking met Betten Beursmedia News (contact: webred@fd.nl/ 020-5928456)

[verwijderd] 17 december 2007 08:50

Dit is goed nieuws. Star leeft dus nog steeds.

clara45 17 december 2007 09:18

[quote=h.vdbilt]
Crucell kondigt licentieovk met ProFribix aan
Crucell: ovk betreft Star technologie

(MORE TO FOLLOW) Dow Jones Newswires

[als crucell doet wat het zegt moet dit vele millioenen opleveren.de koers kan omhoog.
/quote]

sambal 17 december 2007 09:26

zijn er meer mensen met een probleem bij activescreen?? . rt graag van crucell

gogogoo 17 december 2007 09:30

quote:
sambal schreef:
zijn er meer mensen met een probleem bij activescreen?? . rt graag van crucell

Rabo hangt ook met RT.

sappas 17 december 2007 09:34

quote:
sambal schreef:
zijn er meer mensen met een probleem bij activescreen?? . rt graag van crucell

aand. Crucell
Laatste Volume Tijd
Laatste 11,99 390 09:32:29
Verschil -0,26 -2,1224 %
Bied 11,99 360 09:33:27
Laat 12,01 1.778 09:33:27
Hoogste 12,08 09:08:51
Laagste 11,98 09:00:32
Cum. volume --- 20.383
Indicatieve opening ---
Open 11,99 09:00:13
Vorig slot 12,25 14-12-2007
Gemiddelde dagomzet --- 415.610

Bid Ask
Orders Volume Bid Ask Volume Orders
1 360 11,99 12,01 1.778 2
1 600 11,96 12,02 2.304 4
2 7.325 11,95 12,03 602 1
1 3.227 11,94 12,05 925 2
1 290 11,92 12,06 291 1

Groetjes,

Sappas

sambal 17 december 2007 09:35

thanks sappas

sappas 17 december 2007 09:59

Laatste 11,82 200 09:58:13

Groetjes,

Sappas

gogogoo 17 december 2007 09:59

Hallo....een STAR deal.
Gaat weer lekker.

[verwijderd] 17 december 2007 10:05

quote:
gogogoo schreef:
Hallo....een STAR deal.
Gaat weer lekker.

Ja en vooral de koers! ;-)

josti5 17 december 2007 10:18

quote:
debo schreef:
[quote=gogogoo]
Hallo....een STAR deal.
Gaat weer lekker.
[/quote]
Ja en vooral de koers! ;-)

Och, da's 'regel' tegenwoordig: goed PB doet de koers kelderen.

Bovendien: leve Pharming, de indices en de VBR...

wilb52 17 december 2007 10:24

wederom wordt met zeer weinig omzet de koers , fors , onderuit gehaald.
Charttechnisch , de zoveelste false break .
Kortom , de koers kan naar de allerlaagste koersdoelen.
Daar is geen redden meer aan , denk ik.

josti5 17 december 2007 10:30

quote:
wilb52 schreef:
wederom wordt met zeer weinig omzet de koers , fors , onderuit gehaald.
Charttechnisch , de zoveelste false break .
Kortom , de koers kan naar de allerlaagste koersdoelen.
Daar is geen redden meer aan , denk ik.

Compliment voor de timing en de paniek opwekkende inhoud van je postings.

Dat doe je met dit alias overigens alleen bij Crucell...

gogogoo 17 december 2007 10:33

Fibrocaps
ProFibrix' dry powder fibrin sealant
ProFibrix’s primary focus at the moment is on developing Fibrocaps – a new tissue sealant that stops acute and severe bleeding, after trauma injury, for example, or during surgery. Fibrocaps, a mixture of fibrinogen and thrombin, is a unique dry powder formulation that has major advantages over existing liquid tissue sealants: It is easier to prepare and use, is more stable and effective, and can be applied in various ways, including in sprays or bandages.
The current market for surgical application alone is estimated at $ 300 - 400 million per year, and this is expected to double in the next 3-5 years. Because of its unique properties, new markets for Fibrocaps may also be found in emergency settings outside the hospital, such as in ambulances, on battlefields and in the home.
The advantages of Fibrocaps are:
• Ease of preparation and application (particularly on large areas).
• Enhanced and reproducible efficacy due to improved mixing and homogeneity
• Stored as a ready-for-use fibrinogen /thrombin blend at ambient temperatures
• Increased viral safety profile.
• Utility in different presentation formats (e.g. bandages)
8,5 million euro for phase II development
The product has been tested in animal models of liver and spleen surgery and traumatic injury. GMP manufacturing for Fibrocaps is in development and Pharse I/II testing is expected to start by the end of 2008. In march 2007, ProFibrix raised 8,5 million euro funding which is expected to allow for the complete phase II testing of Fibrocaps. Phase III testing is expected to be comple by the beginning of 2010.

Synthocytes

Controlling Internal Bleeding
Synthocytes is a combination of albumin particles and fibrinogen that helps to prevent or stop internal, non-compressible bleeding in various clinical situations.
Synthocytes is designed for treatment of patients with increased risk of internal bleeding caused by blood platelet damage, such as certain oncology and surgery patients. This application represents a € 2 billion market.
A first prototype of the product, based on standard plasma-derived fibrinogen, has demonstrated pre-clinical efficacy in animal models (Levi et al. Nature Medicine 1999; 5: 107-111).

BioCentury
Hemostatic Sprinkles
BioCentury - march 2007 (volume 15, number 14)
ProFibrix thinks its Fibrocaps dry powder fibrin sealant may have a competetive advantage because it can be used off the shelf without rehydrating.
www.profibrix.com/files/Biocentury%20...
crucell.yourbb.nl/viewtopic.php?t=506

[verwijderd] 17 december 2007 10:33

Niet te filmen meer:

Laatste 11,62 200 10:30:17
Verschil -0,63 -5,1429 %
Bied 11,61 74 10:30:17
Laat 11,62 1.900 10:30:17
Hoogste 12,08 09:08:51
Laagste 11,61 10:14:40
Cum. volume --- 90.815
Indicatieve opening ---
Open 11,99 09:00:13
Vorig slot 12,25 14-12-2007
Gemiddelde dagomzet --- 415.610

Bid Ask
Orders Volume Bid Ask Volume Orders
1 74 11,61 11,62 1.900 2
2 801 11,59 11,66 2.000 1
2 1.100 11,57 11,67 1.392 2
1 1.000 11,55 11,68 660 2
2 965 11,54 11,70 200 1

gogogoo 17 december 2007 10:40

"Het enige positieve nieuws is momenteel het herstel van de dollar, wat steun biedt aan de Nederlandse dollar-gerelateerde fondsen", meent de handelaar.

Nou daar zou Crucell ook van moeten profiteren zou ik zeggen......

[verwijderd] 17 december 2007 10:41

Als iemand iets weet van de Star-technologie, dan is het wel Dr.Bram Bout, CTO van Pro/Fibrix!!

wilb52 17 december 2007 10:43

quote:
josti5 schreef:
[quote=wilb52]
wederom wordt met zeer weinig omzet de koers , fors , onderuit gehaald.
Charttechnisch , de zoveelste false break .
Kortom , de koers kan naar de allerlaagste koersdoelen.
Daar is geen redden meer aan , denk ik.
[/quote]

Compliment voor de timing en de paniek opwekkende inhoud van je postings.

Dat doe je met dit alias overigens alleen bij Crucell...

Ik constateer slechts wat er gebeurt, niet meer en niet minder.

33 Posts, Pagina: 1 2 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 860,01 -5,35 -0,62% 19 apr


Germany40^	17.714,20	-0,69%
BEL 20	3.827,75	+0,03%
Europe50^	4.904,14	-0,28%
US30^	37.851,00	0,00%
Nasd100^	17.004,48	0,00%
US500^	4.960,72	0,00%
Japan225^	37.028,48	0,00%
Gold spot	2.392,50	0,00%
EUR/USD	1,0655	+0,11%
WTI	82,10	0,00%